ASCO 2017 | Biosimilars: The future of treating breast cancer
Justin Stebbing, MD, PhD, from Imperial College Healthcare NHS Trust, London, UK talks to us about the findings from a Phase III trial designed to compare the effect of a trastuzumab biosimilar, SB3, to herceptin, in treating HER2-positive breast cancer. He reports a complete response observed in patients receiving the biosimilar without any increase in toxicity, as compared to herceptin-treated patients and adds that adding the biosimilar into the treatment regimen for breast cancer in the future would be desirable due to its cheaper cost and few adverse events reported from its use. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
Get great new content delivered to your inboxSign up